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Background: There is a lack of psychotherapeutic trials of treatments of comorbid depression in cancer patients.
Our study determines the efficacy of a manualized short-term psychodynamic psychotherapy and predictors of
outcome by personality and quality of the therapeutic relationship.
Methods/design: Eligible breast cancer patients with comorbid depression are assigned to short-term
psychodynamic psychotherapy (up to 20 + 5 sessions) or to treatment as usual (augmented by recommendation for
counseling center and physician information). We plan to recruit a total of 180 patients (90 per arm) in two centers.
Assessments are conducted pretreatment, after 6 (treatment termination) and 12 months (follow-up). The primary
outcome measures are reduction of the depression score in the Hospital Anxiety and Depression Scale and
remission of depression as assessed by means of the Structured Clinical Interview for DSM IV Disorders by
independent, blinded assessors at treatment termination. Secondary outcomes refer to quality of life.
Discussion: We investigate the efficacy of short-term psychodynamic psychotherapy in acute care and we aim to
identify predictors for acceptance and success of treatment.
Trial registration: ISRCTN96793588
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Quality of lifeBackground
Breast cancer is associated with multiple losses (e.g.
regarding body image, sexuality, social relationships),
strains (e.g. pain, fatigue) and threat to life. Depressive
disorders are the most frequent mental comorbidities.
The combined prevalence of major, minor depression
and dysthymia in cancer patients was estimated at 22%
[1,2]. In clinical routine, however, depression often
escapes medical attention [3,4]. Without adequate* Correspondence: ruediger.zwerenz@unimedizin-mainz.de
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reproduction in any medium, provided the ortreatment, depressive disorders in medically ill lead to
substantial decrements of quality of life [5], longer in-
patient treatment, prolonged work disability and inad-
equate illness behavior (e.g. lack of compliance) and
even higher mortality [6].
Recently, there has been positive - somewhat limited -
evidence for the effectiveness of pharmacological and
psychotherapeutic treatments with randomized con-
trolled trials (RCT’s) for depressed cancer patients, e.g.
of cognitive behavior and problem-solving therapy for
recently diagnosed, mildly to moderately depressed
patients and of supportive-expressive group therapy for
patients with advanced disease. Studies often suffer from
methodological problems, such as selected or smalll Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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zation or control on treatment adherence. Unfortunately,
only a minority of the trials has adequately assessed de-
pression. A recent study ascertained clear preferences of
cancer patients regarding speaking about their concerns
and fears rather than accepting psychopharmacological
treatment [7].
There has been increasing evidence supporting indi-
vidual supportive-expressive psychotherapy as an effect-
ive short-term psychodynamic psychotherapy (STPP) for
various mental disorders such as depression [8], general-
ized anxiety [9] and social phobia [10]. Based on the
experience of developing a German manual [11] and
training therapists in a multicenter RCT by two authors
(MEB, AH), a specific treatment manual was developed
for treating depression in breast cancer patients [12].
We assumed that psychodynamic treatment is suitable
to deal with the intrapsychic and interpersonal conflicts
generated by the experience of cancer. We also assumed
that maladaptive interpersonal relationship patterns play a
pivotal role in this context and that therapeutic changes of
these patterns lead to remission or improvement of depres-
sion. Also, the combination of interpretative and supportive
treatments renders supportive-expressive psychotherapy
flexible to deal with crises in the course of a potentially life-
threatening disease.
There is still a lack of knowledge on predictors of out-
come of psychotherapy. Blatt & Zuroff [13] found that
the success of short-term outpatient treatment depended
mostly on two factors: the quality of the therapeutic
relationship and patients’ pretreatment personality. In
particular, those patients who were perfectionistic or
self-critical before treatment improved less than those
with low perfectionism. They obviously found it difficult
to relate to their therapists in the time-limited treatment
of depression. Thus, an additional issue of our trial is to
determine the effects of personality and quality of the
therapeutic relationship on treatment outcome.
Methods/design
In a multicenter trial, patients are recruited in the cen-
ters of Mainz and Leipzig in close cooperation with
gynecological and oncological centers in the respective
regions (list of cooperating clinics cf. appendix). Assess-
ments are done by independent, trained and supervised
research-assistants, who are blind to the intervention.
Quality assurance is performed by the independent
Interdisciplinary Center for Clinical Trials with regular
monitoring visits including source data verification of all
randomized patients, control of patient existence and
written consent of all screened patients. Monitoring is
defined in a monitoring manual and all results of the
monitoring are written down in monitor reports.Participants
Members of the oncological teams report eligible con-
secutive patients to trained research assistants. Following
detailed information those who provide written consent
with study participation are entered into the study and
fill out the screening questionnaire. Patients are required
to fulfill the test criteria on the Hospital Anxiety and
Depression Scale (HADS, depression score ≥8) and a
diagnosis of a depressive disorder by the Structured
Clinical Interview for DSM IV Disorders (SCID-I).
Patients are randomized to the intervention or control
group only if a diagnosis of a depressive disorder is made
based on the aforementioned criteria. Inclusion and
exclusion criteria are listed in Table 1.
Intervention
The intervention group is offered a manualized STPP
adapting the approach of Luborsky et al. [8,14] to the
specific needs of depressed breast cancer patients [12].
Following the concept of the Core Conflict Relationship
Theme (CCRT), depression is conceptualized in the con-
text of intrapsychic and interpersonal conflicts. The
CCRT is the treatment focus characterizing a maladap-
tive relationship pattern consisting of a wish, the re-
sponse of the other and of the self. Five pre-treatment
sessions include history taking (also the basis for formal
application to the health insurance) and eliciting rela-
tionship episodes in the relationship interview to formu-
late the CCRT. The treatment agreement is established
in one of the sessions. The therapist shares the CCRT
with the patient, informs him about depression and
about the treatment rationale in order to engage him in
treatment. In the initial treatment phase (sessions 1–6),
the therapist encourages building a positive alliance and
links depressive symptoms to the CCRT. In the middle
phase (sessions 7 to 12), the therapist refines the CCRT
based on further relationship episodes from past, on-
going relationships and the relationship to the therapist.
The vulnerability to depression is reduced when its dy-
namic can be understood from different points of view.
In the termination phase (13 to 18) the therapist focuses
on the issues of separation and the patient’s ability to
transfer the tools acquired in treatment to daily life.
Booster sessions (19, 20) help to consolidate treatment
progress. Treatment principles explicitly specified consider
both the depressed state (e.g. dealing with helplessness/
hopelessness, anger, suicidality, negative attribution style)
and the chronic and life-threatening disease (e.g. realistic
treatment goals, here and now perspective, resource orien-
tation). Psychodynamic therapists are certified or advanced
trainees with psycho-oncological experience. They are
trained in the manualized treatment during workshops be-
fore starting treatments and are regularly supervised dur-
ing the treatments. For the supervision, each patient
Table 1 Inclusion and exclusion criteria




• Depression score (HADS≥ 8)
• Depressive disorder according to SCID-I (ICD-10 diagnoses: depressive episode F32.-, recurrent depressive episode
F33.-; Dysthymia F34.1, adjustment disorder F43.21)
• Written consent with study participation
Exclusion criteria: • Severe medical conditions (metastases, cognitive impairments)
• Severe psychiatric disorders (psychotic disorder, risk of self-harm /suicide, acute substance related disorder, personality
disorders except for cluster C, organic mental disorder)
• Concurrent psychotherapeutic treatment
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points (formulation of the CCRT after the relationship
interview, in the middle phase of STPP and in the termin-
ation phase of STPP). Supervision is free of charge for the
participating psychotherapists. Each session is videotaped.
For the evaluation of treatment adherence and competence
cf. assessment.
Assessments
At baseline, patients fill out the HADS [15] in the
German version (HADS-D) [16], a standardized ques-
tionnaire devised for the assessment of depression and
anxiety in somatic illness with 14 items. Quality of life is
assessed by the generic 30-item questionnaire of the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire - Core 30 (EORTC
QLQ-C30) [17] differentiating a global health status,
functioning (physical, role, emotional, cognitive, social)
and symptoms (e.g. fatigue, nausea and vomiting, pain
etc.). Furthermore, the breast cancer specific quality of
life module (EORTC QLQ-BR23) [18] which consists of
functional scales (body image, sexual functioning, sexual
enjoyment, future perspective) and symptom scales (sys-
tem therapy side effects, breast symptoms, arm symp-
toms and upset by hair loss) is used. The validated
German version of the Depressive Experience Ques-
tionnaire (DEQ) [19] is used to identify prognostically
relevant personality dimensions of dependency (loneli-
ness, helplessness, fear of rejection), perfectionism or
self-criticism (worthlessness, failure, guilt, critical self-
monitoring) and self-efficacy (ambitious, competitive
and self-reliant stance). The Multidimensional Fatigue
Inventory (MFI) [20] is a 20 item self-report instrument
covering the dimensions general fatigue, physical fa-
tigue, reduced activity, reduced motivation and mental
fatigue. The German version [21] of the Helping Alliance
Questionnaire (HAQ) [14] an 11-item rating scale for
assessing perceptions of the therapeutic relationship andprocess is filled out by the patient and therapist at the end
of psychotherapy. The Structured Clinical Interview for
DSM-IV [22] is used for standardized (‘gold standard’) as-
sessment of axis I diagnoses. The PACS-SE (Penn Adher-
ence/Competence Scale) with 45 Items [23] is used in the
German version [24] for independent assessment of ther-
apist adherence and competence based on randomly
selected videotaped therapy sessions.
Objectives
The main purpose of the ongoing trial is to determine
the efficacy of the manualized STPP regarding remission
of depression in breast cancer patients. Secondary out-
comes refer to changes of quality of life and to the effect
of subtype of depression on treatment outcome.
Based on non-responder analyses we intend to answer
the question, which patients do not accept psychothera-
peutic treatment for what reason and which characteris-
tics (e.g. age, marital, social status, illness variables, type
of depression) have an impact on treatment outcome?
Hypotheses
Primary outcome:
1) Higher rate of remission in STPP vs. ‘treatment as
usual’ (TAU) at treatment termination.
Secondary outcomes:
2) Six months after the end of treatment lower rate of
depression and a higher quality of life among the
STPP group compared to TAU.
3) Better outcome in dependent/anaclitic vs. self-
critical/ perfectionistic depression (DEQ).
Study design
In the multicenter randomized prospective trial breast
cancer patients with comorbid depression who fulfill
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an overview of the study design, time-points of assess-
ments measures used and projected numbers.
We plan to recruit N = 90 participants per group. To
ensure adequate randomization stratified for the center,
the random assignment to STPP or TAU was performed
separately by research staff from the responsible centerTest of inclusion/ exclusion
Study information & written
HADS ≥ 8
HADS, DEQ, EORTC QLQ-C30
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a regular basis. Intensive training (at least 2 x 2 hours) is
performed in a group format by the respective local
study center prior to entering the first patient. Supervi-
sion is performed on a monthly basis (3 hours) in the
group. In order to assure adherence to the manual, it is
recommended that therapists present patients in super-
vision three times (initial formulation of CCRT based on
relationship episode interview, middle and termination
phase of treatment).
Patients randomized to the TAU condition are not
offered STPP, but obtain written information on local
cancer counseling centers and get written information
on psychodiagnostic findings to their general practi-
tioner who may then initiate antidepressant treatment
(‘as usual’). Utilization of medical, psychotherapeutic and
psychopharmacological treatment is documented through-
out the study.
Outcome
Remission of depression is defined by reduction of the
HADS depression-score (at least by 2 points) and re-
mission of depression (SCID-I-diagnosis) at treatment
termination.
Sample size calculation
While planning this study no meaningful published data
on remission rates for STPP vs. TAU for the treatment
of depression in breast cancer were available. For STPP
of depression remission rates between 45% and 70% at
post-therapy assessment were published [26], while re-
mission rates in primary-care settings (comparable to
TAU) ranged between 20% and about 50% (6 months)
[27-29]. For patients with complex medical illness like
cancer and co-morbid depressive disorders we expect
lower remission rates for TAU and also for STPP. For
this highly burdened population we pragmatically
expected a spontaneous remission rate of 25% for TAU
and 50% for STPP in our sample size calculation.
In order to identify group differences of 25% (25%
remission in TAU vs. 50% in STPP) as based on χ2-Test
(two-tailed) and a power of 0.80 a total sample of
N = 156 is required, taking into account a slightly higher
dropout rate of 30% in the TAU group vs. a 20% in
STPP.
Statistical analyses
The primary endpoint remission after the treatment
phase will be analyzed by a logistic regression with fixed
effects for treatment and center and the baseline HADS
value as covariate. The primary population for analysis
will be the population intended to treat (ITT) consisting
of all randomized patients. Dropouts will be regarded
as non-remitters. For sensitivity the analysis will berepeated for the completers of treatment population.
Additionally, the single components (HADS improve-
ment of ≥2 points, remission according to SCID) will be
analyzed separately by the same analysis model as the
combined endpoint.
Secondary analyses include the remissions at the end
of the follow-up. Remissions at the end of the follow-up
will be evaluated accordingly. The quality of life (QoL)
questionnaires will be analyzed by an analysis of covari-
ance (ANCOVA) model with fixed effects for treatment
and center and the baseline values (HADS depression
score & Qol) as covariates. It is expected that the QoL
questionnaires will not be linear across the study. There-
fore QoL questionnaires after the follow-up will be eval-
uated by a linear model with fixed effects for treatment,
center and time. There will be an indicator variable for
the post treatment visit. The HADS value at baseline will
serve as a covariate. For QoL data the observed values
will be analyzed. However, if the number of missing data
is more than 10%, the data will be evaluated after mul-
tiple imputation of the data by a Markov chain Monte
Carlo (MCMC) method. The impact of moderator vari-
ables (age, marital, social status, illness variables, type of
depression) is tested in regression analyses.
Safety aspects and medical complications
Safety parameters will comprise newly occurring mental
diagnoses and all serious adverse events that are
reported during and up to six months after treatment.
The recording of adverse events will be restricted to
psychological conditions. Formally, they are defined as
any disorder classified by the International Classification
of Diseases F00 - F99. A serious adverse event (SAE) is
an adverse event that may occur at any time of the treat-
ment phase or up to 6 months after end of treatment:
results in death; is life-threatening; requires subject
hospitalization or prolongation of existing hospitalization;
results in persistent or significant disability/incapacity; is
a congenital anomaly/birth defect.
Any SAE (according to the study specific definition)
reported by the subject or detected by the local investi-
gator will be collected during the trial and must be
documented in case report forms. ICD-10 will be used
by the local investigator to code the event. The clinical
course of the SAE will be followed until it has changed
to a stable condition or until end of follow-up phase,
whatever comes first. In case of SAEs the Ethics Com-
mittee will be informed within 24 hours after the SAE
becomes known.
Ethical issues
The final study protocol and the final version of the
written informed consent form were approved by the
Ethics Committee of the Federal State of Rhineland-
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(5478)] and the Ethics Committee of the University of
Leipzig [reference number 218–2007]. The procedure
set out in this protocol, pertaining to the conduct, evalu-
ation, and documentation of this trial, were designed to
ensure that all persons involved in the trial abide by
Good Clinical Practice and the ethical principles
described in the current revision of the Declaration of
Helsinki [30]. The trial will be carried out in keeping
with local legal and regulatory requirements. Before
being admitted to the clinical trial, patients must con-
sent to participate after the nature, scope, and possible
consequences of the clinical trial have been explained in
a form understandable to them. The patients must give
written informed consent to participate in the study in-
cluding their consent to publish.Discussion
This is the first trial to determine the efficacy of a man-
ualized STPP regarding remission of depression in breast
cancer patients. Secondary outcomes refer to changes of
quality of life and to the effect of subtype of depression
on treatment outcome. Unlike previous studies we
required a diagnosis of depression for study entry and
we used remission of depression as a clinically relevant
outcome criterion.
As we wish to contribute to evidence-based psycho-
oncological care we chose as a control condition treat-
ment as usual. We are aware that quality of care for the
individual patient in the control condition may vary.
However, we actually perform an augmented TAU con-
dition by referring patients to a collaborating cancer
counseling center which may provide individual counsel-
ing or further referral. We also take great care to send
written and detailed findings on the comorbid depres-
sion diagnosis to the general practitioner of all the
patients (IG and CG) who have given their written con-
sent to do so. We make sure that we carefully assess the
actual health care utilization by all patients during both
follow-ups.
As we planned to provide an intervention for acute
care, we recruit patients who are still in active treatment
(chemotherapy, radiotherapy). Recruiting in the major
local clinics we make sure that we could assess and con-
tact the breast cancer patients with comorbid depres-
sion. We are aware, however, that a substantial
proportion of patients would refuse study participation
feeling strongly burdened by ongoing treatment. Based
on non-responder analyses we intend to answer the
question, which patients do not accept psychothera-
peutic treatment for what reason [31]. Including the im-
portant dimensions of therapeutic alliance and personality
dimensions shaping the experience and expression ofdepression we also ascertain who benefits most from
treatment.
Previous studies of STPP adapting the approach of
Luborsky et al. [8,14] found no sex differences regarding
treatment response [9]. Supportive-expressive psycho-
therapy has proven a robust model of short-term treat-
ment for a diverse range of mental disorders. We
therefore anticipate that it will be possible to transfer
the treatment manual also to other kinds of cancer with
comorbid depression less frequently studied - particu-
larly in men.
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